Galapagos NV (PK) (GLPGF) Fundamentals

Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti-infectives. Galapagos' approach is to develop drugs that stop or reverse a disease state using novel targets that are identified through a patent protected target discovery platform. Galapagos also provides access to its target and drug discovery platform through its services division, BioFocus and Argenta, which offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies.
Share Info
Market Cap$ 1,438,927,651
Shares Authorized-
Shares Outstanding26,770,747
Shares Outstanding Date12/31/2012
Shareholder Count-
Shareholder Count Date-
Float Date-
Short Interest196,822
Short Interest Date07/15/2022
Reporting Info
Reporting StatusSEC Reporting
Audit StatusYes
Auditor Address-
Auditor Website-
IR Firm-
IR Firm Address-
IR Firm Website-
Legal Counsel-
Legal Counsel Address-
Legal Counsel Website-
Fiscal Year End12/31
ADR Ratio-
Transfer Agent-
Transfer Agent Address-
Depository Website-
SHO Flag-
3210 Flag-
Company Info
Ticker SymbolUSOTC:GLPGF
OTC Market TierPink Current
Security TypeOrdinary Shares
CIK Number0001421876
AddressIndustriepark Mechelen Noord
Generaal De Wittelaan L11 A3
Phone+32 1 534 29 00
Fax #+32 15 34 29 01
SIC Code / Description2834 / Pharmaceutical preparations
Key ExecutivesChairman - Raj Parekh
IR Manager - Elizabeth Goodwin
CEO - Onno van de Stolpe
CFO - Guillaume Jetten
Number of Employees830
Incorporation State-
Incorporation CountryBelgium
Incorporation Year1999
Your Recent History
Galapagos ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now
NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20220813 15:25:18